In addition to HER2, signaling from other HER members19 is important in activating the HER pathway, and we previously reported that combining a HER1 inhibitor (e.g., gefitinib) with the HER2 mAbs T and P further enhanced the anti-tumor efficacy and accelerated tumor eradication7. Here, EGFR is linked to neoplasm.